Innate Pharma : Corporate Presentation | May 2021

Company Overview

May 2021

PARIS: IPH.PA

NASDAQ: IPHA

© 2020 Innate Pharma. All rights reserved.

Disclaimer on Forward-Looking Information and Risk Factors

This document has been prepared by Innate Pharma S.A. (the "Company") solely for the purposes of a presentation to investors concerning the Company. This document is not to be reproduced by any person, nor to be distributed.

This document contains forward-looking statements. The use of certain words, including "believe," "potential," "expect" and "will" and similar expressions, is intended to identify forward- looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to various risks and uncertainties, which could cause the Company's actual results or financial condition to differ materially from those anticipated. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related to safety, progression of and results from its ongoing and planned clinical trials and preclinical studies, review and approvals by regulatory authorities of its product candidates, the Company's commercialization efforts and the Company's continued ability to raise capital to fund its development. For an additional discussion of risks and uncertainties which could cause the Company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the Universal Registration Document filed with the Autorité des Marchés Financiers ("AMF"), available on the AMF website (www.amf-france.org) or on the Company's website (www.innate-pharma.com), and public filings and reports filed with the U.S. Securities and Exchange Commission ("SEC"), including the Company's Annual Report on Form 20-F for the year ended December 31, 2020, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public, by the Company. Such documents may not be necessarily up to date.

This document contains data pertaining to the Company's potential markets and the industry and environment in which it operates. Some of this data comes from external sources that are recognized in the field or from Company's estimates based on such sources.

This presentation discusses product candidates that are under clinical development and which have not yet been approved for marketing by the U.S. Food and Drug Administration or the European Medicines Agency. No representation is made as to the safety or effectiveness of these product candidates for the use for which such product candidates are being studied.

The information contained herein has not been independently verified. No representation, warranty or undertaking, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained herein. The Company is under no obligation to keep current the information contained in this presentation and any opinion expressed is subject to change without notice.

The Company shall not bear any liability whatsoever for any loss arising from any use of this document or its contents or otherwise arising in connection therewith.

This document and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares of the Company in any country.

2

A Leading Company in the Field of Innate Immunity

• Global, clinical-stageoncology-focused biotech company.
• Scientific excellence in the field of innate immunity with expertise in natural killer cell biology and antibody engineering.
• Focused pipeline of antibodies, including several potentially first-in-class clinical and preclinical candidates in cancers with high unmet medical need.

M A R S E I L L E F R A N C E

R O C K V I L L E M A R Y L A N D

Founded: 1999

Paris Euronext listing: 2006

Nasdaq listing: 2019

3

Scientific Innovation Drives Our Strategy

We aim to harness our scientific know-how in innate immunity and antibody engineering

to develop oncology products that improve the lives of patients

Drive near-term		Advance our		Build a
value with		innovative R&D		sustainable
Lacutamab		pipeline		business

4

Strong Science + Strong Partnerships = Robust Pipeline

Validated	Strong Track	Robust
Science	Record of	Pipeline
in high-impact	Collaborations	with innovative
publications	with industry and	pre-clinical and
	clinical assets
	academia

5